REFERENCES
- Velez DA, Mayberg MR, Ludlam WH. Cyclic Cushing's syndrome: definitions and9.treatment implications. Neurosurg Focus 2007; 23: E4–6.
- Albinger NM, Scaroni CM, Mantero F. Cyclic Cushing's syndrome: an overview. Arq Bras Endocrinol Metab 2007; 51: 1253–1260.
- Yasuda K. Cyclic Cushing's disease: pitfalls in the diagnosis and problems with the pathogenesis. Intern Med 1996; 35: 169–170.
- Meinardi JR, Wolffenbuttel BH, Dullaart RP. Cyclic Cushing's syndrome: a clinical challenge. Eur J Endocrinol 2007; 157: 245–254.
- Boscaro M, Barzon L, Fallo F, Sonino N. Cushing's syndrome. Lancet 2001; 357: 783–791.
- Mantero F, Scaroni CM, Albiger NM. Cyclic Cushing's syndrome: an overview. Pituitary 2004; 7: 203–207.
- Lacroix A, Bourdeau I. Bilateral adrenal Cushing's syndrome: macronodular adrenal hyperplasia and primary pigmented nodular adrenocortical disease. Endo-15.crinol Metab Clin North Am 2005; 34: 441–458.
- Nieman LK, Biller BM, Findling JW et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526–1540.
- Castro M, Moreira AC. Screening and diagnosis of Cushing's syndrome. Arq Bras Endocrinol Metabol 2007; 51: 1191–1198.
- Newell-Price J, Trainer P. Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19: 647–672.
- van Rossum EF, Lamberts SW. Glucocorticoid resistance syndrome: A diagnostic and therapeutic approach. Best Pract Res Clin Endocrinol Metab 2006; 20:611–626.
- Arnaldi G, Boscaro M. Pasireotide for the treatment of Cushing's disease. Expert Opin Inyestig Drugs 2010; 19: 889–898.
- Czapiński P. Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005; 5:3–14.
- Schteingart DE. Drugs in the medical treatment of Cushing's syndrome. Expert Opin Emerg Drugs 2009; 14:661–671.
- Del Dotto P. Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Phar-macokinet 2003; 42: 633–645.